Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants

NCT03445208 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03445208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03445208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Completed
Start date
February 14, 2018
Completion date
May 2, 2018
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic cirrhosis, liver fibrosis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis